Arca
Skip to content
Tools
Tools

Shock

Drug research and approvals for shock: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 389 studies of shock are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, FDA has 0 approved and 4 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 389
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest start dates first, of 389 recruiting on ClinicalTrials.gov ↗

Drug pipeline

1 approved, 13 in phase 3, 8 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Angiotensin ii

Norepinephrine
Phase 3 Adrenergic receptor agonist
Vasopressin
Phase 3 Vasopressin receptor agonist
Tranexamic acid
Phase 3 Plasminogen inhibitor
Levosimendan
Phase 3 Phosphodiesterase 3 inhibitor
Dopamine
Phase 3 Beta-1 adrenergic receptor agonist
Empagliflozin
Phase 3 Sodium/glucose cotransporter 2 inhibitor
Tilarginine
Phase 3 Nitric oxide synthase inhibitor
Fibrinogen, human
Phase 3 Fibrinogen exogenous protein
Oxygen
Phase 3 Essential for cellular homeostasis
Dextran 70
Phase 3
Dobutamine
Phase 2 Beta-1 adrenergic receptor agonist
Heparin
Phase 2 Antithrombin-III activator
Istaroxime
Phase 2 Sodium/potassium-transporting ATPase inhibitor
Nitroglycerin
Phase 2 Soluble guanylate cyclase activator
Estrogens, conjugated
Phase 2 Estrogen receptor agonist
Epinephrine
Phase 2 Adrenergic receptor agonist
Albumin human
Phase 2 Bilirubin sequestering agent
Ascorbic acid
Phase 2 Supplement
Valproic acid
Phase 1 Succinate semialdehyde dehydrogenase inhibitor
Propofol
Phase 1 GABA-A receptor; anion channel positive allosteric modulator
Aluminum hydroxide
Phase 1 Antacid

How its trials ended

952 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 192 whose ending is known, 30% met their primary endpoint, 21% missed it and 49% stopped early.

  • Completed, result not reported33235%
  • Ongoing21923%
  • Status unknown20922%
  • Met its primary endpoint576%
  • Stopped: other or unclear475%
  • Missed its primary endpoint414%
  • Stopped: enrollment or feasibility263%
  • Stopped: lack of efficacy101%
  • Stopped: funding51%
  • Stopped: sponsor or business decision40%
  • Stopped: safety20%

Trials authorized in Canada

Newest first; search them all in Canada trials
Dec 15, 2025Beta-blocker therapy versus standard care in patients with septic shock: a pilot randomized controlled trial utilizing predictive enrichment with point-of-care…EsmololLondon Health Sciences CentreOngoing
Dec 17, 2024Adjunctive methylene blue in septic shock (BLUSH): a pilot randomized controlled trialMethylene blueDr Shannon Mario FernandoPending
Feb 24, 2022Umbilical mesenchymal stromal cells as cellular immunotherapy for septic shock (uc-ciss ii): a multi-center, double-blind, phase II randomized controlled trialAllogenic umbilical cord mesenchymal stromal cells (uc-mscs)Ottawa Hospital Research InstituteOngoing
Apr 26, 2021Pragmatic pediatric trial of balanced versus normal saline fluids in sepsis (prompt bolus)Plasma-lyte a/ Lactated ringer's/ Sodium chlorideGovernors of The University of CalgaryOngoing
Aug 3, 2017Heparin anticoagulation to improve outcomes in septic shock: the halo international phase II rctHeparin sodiumUniversity of ManitobaOngoing
Apr 1, 2015Treatment of septic shock by inhibiting autodigestion and preserving gut integrity with enteric LB1148 (ssail study)LB1148 (tranexamic acid)Leading Biosciences IncOngoing
Dec 19, 2014Cellular immunotherapy for septic shock (CISS)Allogeneic mesenchymal stromal cells (MSCS)Ottawa Hospital Research InstituteOngoing

FDA orphan designations

Approved first, then open designations, newest first
Aug 6, 2013Conjugate of a dengue virus specific small chemical ligand…Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome)NanoViricides IncorporatedDesignated
Dec 18, 2007Hemoximer (pyridoxalated hemoglobin polyoxyethylene)Treatment of cardiogenic shockApex Bioscience, Inc.Designated
Apr 11, 2005Tilarginine acetateTreatment of cardiogenic shockArginox Pharmceuticals, Inc.Designated
Nov 4, 1985Monoclonal antiendotoxin antibody XMMEn-0e5Treatment of patients with gram-negative sepsis which has progressed to shock.Pfizer, Inc.Designated

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Aug 23, 2019GiaprezaAngiotensin IIPaion Pharma GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.